{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:16:21Z","timestamp":1789748181891,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672930"],"award-info":[{"award-number":["81672930"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871976"],"award-info":[{"award-number":["81871976"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872435"],"award-info":[{"award-number":["81872435"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20377"],"award-info":[{"award-number":["U20A20377"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009993","name":"Excellent Youth Foundation of Heilongjiang Province of China","doi-asserted-by":"publisher","award":["JQ2019H003"],"award-info":[{"award-number":["JQ2019H003"]}],"id":[{"id":"10.13039\/501100009993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cellimm.2021.104384","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T11:35:39Z","timestamp":1621769739000},"page":"104384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer"],"prefix":"10.1016","volume":"366","author":[{"given":"Jiaqi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binlin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongsen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2021.104384_b0005","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA: A Cancer Journal for Clinicians, 69 (2019) 7-34.","DOI":"10.3322\/caac.21551"},{"key":"10.1016\/j.cellimm.2021.104384_b0010","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transd. Target. Ther."},{"key":"10.1016\/j.cellimm.2021.104384_b0015","doi-asserted-by":"crossref","unstructured":"R. C, T. C, S.-W. H, R. NN, K. M, K. F, R. F, E. L, D. J, B. MW, B. P, H. PE, W.J. J. B. cancer, A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer BMC Cancer, 11 (2011) 419.","DOI":"10.1186\/1471-2407-11-419"},{"key":"10.1016\/j.cellimm.2021.104384_b0020","doi-asserted-by":"crossref","unstructured":"R. S, P.-L. B, G.-L. A, N. S, S. ML, G. A, C. S, G. N, B. D, M. G, L. MP, P. J, C. E, B. R, W. L, K. J, O. G, D. M, D.P. M, P. TV, Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice, J. Clin. Invest., 130 (2020) 1199-1216.","DOI":"10.1172\/JCI129558"},{"key":"10.1016\/j.cellimm.2021.104384_b0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2021.104384_b0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jmoldx.2011.11.001","article-title":"Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas","volume":"14","author":"Funkhouser","year":"2012","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cellimm.2021.104384_b0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-017-0454-7","article-title":"Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress","volume":"10","author":"Myint","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellimm.2021.104384_b0040","doi-asserted-by":"crossref","unstructured":"A.C. A, C.A. B, D.T.T. B, Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy, Pharmacol. Ther. 194 (2019) 84\u2013106.","DOI":"10.1016\/j.pharmthera.2018.09.008"},{"key":"10.1016\/j.cellimm.2021.104384_b0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0050","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellimm.2021.104384_b0055","doi-asserted-by":"crossref","unstructured":"J. Fu, D.B. Kanne, M. Leong, L.H. Glickman, S.M. McWhirter, E. Lemmens, K. Mechette, J.J. Leong, P. Lauer, W. Liu, K.E. Sivick, Q. Zeng, K.C. Soares, L. Zheng, D.A. Portnoy, J.J. Woodward, D.M. Pardoll, T.W. Dubensky, Jr., Y. Kim, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Sci. Transl. Med., 7 (2015) 283ra252.","DOI":"10.1126\/scitranslmed.aaa4306"},{"key":"10.1016\/j.cellimm.2021.104384_b0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nature10429","article-title":"STING is a direct innate immune sensor of cyclic di-GMP","volume":"478","author":"Burdette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2021.104384_b0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","article-title":"Structures and mechanisms in the cGAS-STING innate immunity pathway","volume":"53","author":"Zhang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2021.104384_b0075","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","article-title":"cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING","volume":"498","author":"Ablasser","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2021.104384_b0080","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.7150\/thno.37574","article-title":"STING activation in cancer immunotherapy","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.cellimm.2021.104384_b0085","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2021.104384_b0090","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/2326-6066.CIR-13-0123","article-title":"STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer","volume":"2","author":"Chandra","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2021.104384_b0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0100","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2021.104384_b0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellimm.2021.104384_b0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1158\/2326-6066.CIR-14-0099","article-title":"STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment","volume":"2","author":"Ohkuri","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2021.104384_b0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2021.104384_b0120","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1189801","article-title":"c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response","volume":"328","author":"Woodward","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2021.104384_b0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2014.04.004","article-title":"A new adjuvant delivery system 'cyclic di-GMP\/YSK05 liposome' for cancer immunotherapy","volume":"184","author":"Miyabe","year":"2014","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.cellimm.2021.104384_b0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2021.104384_b0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellimm.2021.104384_b0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2021.104384_b0145","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","article-title":"STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0150","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/2326-6066.CIR-17-0049","article-title":"Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity","volume":"5","author":"Ager","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2021.104384_b0155","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2021.104384_b0160","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2020.04.004","article-title":"Opportunities for small molecules in cancer immunotherapy","volume":"41","author":"van der Zanden","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cellimm.2021.104384_b0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1568026619666190308131805","article-title":"Small-molecule immuno-oncology therapy: advances, challenges and new directions","volume":"19","author":"Chen","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.cellimm.2021.104384_b0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"Journal of hematology & oncology"},{"key":"10.1016\/j.cellimm.2021.104384_b0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cellimm.2021.104384_b0180","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2021.104384_b0185","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2021.104384_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001182","article-title":"Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity","volume":"8","author":"Lemos","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0195","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1182\/blood-2005-04-1403","article-title":"Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis","volume":"106","author":"Potula","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2021.104384_b0200","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1039\/C7MT00105C","article-title":"Heme-containing enzymes and inhibitors for tryptophan metabolism","volume":"9","author":"Yan","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.cellimm.2021.104384_b0205","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1080\/15384047.2019.1632143","article-title":"CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis","volume":"20","author":"Shi","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cellimm.2021.104384_b0210","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.7150\/jca.31727","article-title":"Role of IDO and TDO in cancers and related diseases and the therapeutic implications","volume":"10","author":"Ye","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0215","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.7150\/jca.32806","article-title":"STING signaling is a potential immunotherapeutic target in colorectal cancer","volume":"10","author":"Chon","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.cellimm.2021.104384_b0220","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2021.104384_b0225","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41467-017-00101-w","article-title":"TRIM29 promotes DNA virus infections by inhibiting innate immune response","volume":"8","author":"Xing","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2021.104384_b0230","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2021.104384_b0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2018.11.003","article-title":"An analysis of the expression and association with immune cell infiltration of the cGAS\/STING pathway in pan-cancer","volume":"14","author":"An","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.cellimm.2021.104384_b0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay9013","article-title":"cGAS-STING-mediated DNA sensing maintains CD8 T cell stemness and promotes antitumor T cell therapy","volume":"12","author":"Li","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2021.104384_b0245","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2019.02.029","article-title":"STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity","volume":"450","author":"Pei","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellimm.2021.104384_b0250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.cellimm.2021.104384_b0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2018.05.005","article-title":"Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells","volume":"431","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellimm.2021.104384_b0260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2021.104384_b0265","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/cas.12705","article-title":"Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice","volume":"106","author":"Takamatsu","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellimm.2021.104384_b0270","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3389\/fimmu.2020.01185","article-title":"Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies","volume":"11","author":"Zhai","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874921001039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874921001039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T18:22:52Z","timestamp":1762107772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874921001039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":54,"alternative-id":["S0008874921001039"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2021.104384","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2021.104384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104384"}}